Butyrylcholinesterase K Variant and Alzheimer’s Disease Risk: A Meta-Analysis
Butyrylcholinesterase K Variant and Alzheimer’s Disease Risk: A Meta-Analysis
复制标题
丁酰胆碱酯酶 K 变体与阿尔茨海默病风险：荟萃分析
DOI：
10.12659/msm.892982
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Jinlian Wang
中科院分区：
文献类型：
--
作者：
Zongcheng Wang;Yuren Jiang;Xi Wang;Yangsen Du;Dandan Xiao;Youchao Deng;Jinlian Wang
背景虽然许多研究已经估计了丁酰胆碱酯酶（BCHE）K变异与阿尔茨海默病（AD）风险之间的关联，但结果仍存在争议。因此，我们进行了这项荟萃分析。材料/方法我们检索了NCBI、Medline、Web of Science和Embase数据库，以找到所有符合条件的研究。比值比（OR）和95%置信区间（CI）用于评估关联的强度。结果BCHE K变异与AD发病风险有显著相关性（OR=1.20，95%CI 1.03-1.39，P=0.02）。在按种族分层分析中，我们观察到亚洲人的BCHE K变异与AD风险之间存在显著相关性（OR=1.32; 95%CI 1.02-1.72; P=0.04）。然而，在高加索人群中，BCHE K变异与AD风险无显著相关性（OR=1.14; 95%CI 0.95-1.37; P=0.16）。当按AD发病年龄分层时，我们发现晚发AD（LOAD）与BCHE K变异显著相关（OR=1.44; 95%CI 1.05-1.97; P=0.02）。未观察到BCHE K变异体与早发性AD（EOAD）风险之间的显著相关性（OR=1.16; 95%CI 0.89-1.51; P=0.27）。与非APOE β 4和非BCHE K携带者相比，BCHE K变异与AD风险无显著相关性（OR=1.11，95%CI 0.91-1.35，P=0.30）。然而，非BCHE K携带者（OR=2.81; 95%CI 1.75-4.51; P=0.0001）和BCHE K携带者（OR=3.31; 95%CI 1.82-6.02; P=0.0001）中APOE β 4携带者显示AD风险增加。结论BCHE K变异可能与AD的发病风险有关。
Background Although many studies have estimated the association between the butyrylcholinesterase (BCHE) K variant and Alzheimer’s disease (AD) risk, the results are still controversial. We thus conducted this meta-analysis. Material/Methods We searched NCBI, Medline, Web of Science, and Embase databases to find all eligible studies. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association. Results We found a significant association between BCHE K variant and AD risk (OR=1.20; 95% CI 1.03–1.39; P=0.02). In the stratified analysis by ethnicity, we observed a significant association between BCHE K variant and AD risk in Asians (OR=1.32; 95% CI 1.02–1.72; P=0.04). However, no significant association between BCHE K variant and AD risk in Caucasians was found (OR=1.14; 95% CI 0.95–1.37; P=0.16). When stratified by the age of AD onset, we found that late-onset AD (LOAD) was significantly associated with BCHE K variant (OR=1.44; 95% CI 1.05–1.97; P=0.02). No significant association between BCHE K variant and early-onset AD (EOAD) risk was observed (OR=1.16; 95% CI 0.89–1.51; P=0.27). Compared with non-APOE ɛ4 and non-BCHE K carriers, no significant association between BCHE K variant and AD risk was found (OR=1.11; 95% CI 0.91–1.35; P=0.30). However, APOE ɛ4 carriers showed increased AD risk in both non-BCHE K carriers (OR=2.81; 95% CI 1.75–4.51; P=0.0001) and BCHE K carriers (OR=3.31; 95% CI 1.82–6.02; P=0.0001). Conclusions The results of this meta-analysis indicate that BCHE K variant might be associated with AD risk.